Category Archives: Business and Investments

Latest From Business and Investments

Perspective on Market Valuation for Biotech Drug Developers

Graph

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% are working on molecular tools, diagnostics, biofuels, and other biotech endeavors. One question that is often asked with respect to drug-focused biotechs is: How big are they compared to traditional pharmaceutical companies? How many are valued as small start-ups vs large, or mid-size pharmas? It turns out that more than half the sector trades with a market valuation of less Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Boosting Investment in Biotech

Biofuel Research

The President’s Council on Jobs and Competitiveness issued an interim report with suggestions to increase job creation and growth in the U.S., as well as plans for encouraging investment in the industry. Of particular interest to the biotech industry, the report offers suggestions for streamlining the FDA approval process. The report also outlines ideas for eliminating capital gains on investments of $25 million or less that are held for at least five years and recommends Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BayBio Announces Lifetime Achievement DiNA Award Recipient

BayBio

Dr. Michael Hunkapiller has been named BayBio’s 2011 Lifetime Achievement DiNA Award recipient. He will be honored on Thursday, November 3rd, at the 2011 Pantheon Awards Ceremony, an annual program hosted by BayBio, a life science trade association representing the industry in Northern California. From the invention of the DNA sequencer during his days at Caltech, to the introduction of first automated DNA sequencer in 1986 and the realization of the Human Genome Mapping Project Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Increasing Partnering at BIO

Partnering Meetings

Mike May from Biotech Tallies writes: At the 2011 BIO International Convention, the number of one-on-one partnering meetings soared to 21,183… The increasing number of such meetings probably reflects the growth in biotechnology, the escalating importance of BIO’s annual meeting and the expanding need to partner for success in this field.

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Biotech IPO Window – Still Ajar?

IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue to drop and investors shy away from risk. This is the fifth IPO withdrawal since June. Ambit, Agendia and Clarus cited market reasons for their withdrawals, and Advanced BioHealing sought a higher valuation exit via acquisition. Only one biotech IPO, Horizon Pharma, has made it out in the last six months. Of the nine biotech IPOs so far in 2011, Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,